Literature DB >> 29438906

Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancer.

Ewelina Motylewska1, Tomasz Stępień2, Magdalena Borkowska2, Krzysztof Kuzdak2, Agnieszka Siejka3, Jan Komorowski3, Henryk Stępień4, Hanna Ławnicka4.   

Abstract

INTRODUCTION: βKlotho (βKL) is known to act as co-receptor for fibroblast growth factor receptor 4 (FGFR4) which is the main cognate receptor for fibroblast growth factor 19 (FGF19). Dysregulation of this FGF19/FGFR4/βKL signaling axis has been implicated in the pathogenesis of several cancers. However, its role in the pathogenesis of thyroid cancer has not been determined.
MATERIALS AND METHODS: The aim of this study was to assess FGF19, FGFR4 and βKL concentrations in a group of 36 patients with papillary thyroid cancer (PTC), 11 patients with follicular thyroid cancer (FTC), 9 patients with anaplastic thyroid cancer (ATC) and a group of 19 subjects with multinodular nontoxic goiter (MNG). The control group consisted of 20 healthy volunteers. Serum FGF19, FGFR4 and βKL concentrations were measured using specific ELISA methods.
RESULTS: Significantly lower concentrations of βKL and higher concentrations of FGF19 were found in patients with PTC, FTC and ATC as compared with MNG group and controls. An elevation of FGFR4 serum concentration was observed in all thyroid cancer groups in comparison to MNG group and controls; however, in FTC group it was statistically insignificant. A positive correlation was found between βKL and FGFR4 concentrations in PTC patients. The levels of βKL, FGF19 and FGFR4 did not differ significantly between MNG group and healthy controls.
CONCLUSIONS: Our results indicate that a disrupted FGF19/FGFR4/βKL signaling pathway may play a role in the development of thyroid cancers. However, further studies are needed to elucidate the molecular mechanism of the neoplastic transition of thyroid epithelial cells.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FGF19; FGFR4; Serum concentration; Thyroid cancer; βKlotho

Mesh:

Substances:

Year:  2018        PMID: 29438906     DOI: 10.1016/j.cyto.2018.02.013

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  11 in total

Review 1.  Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases.

Authors:  Min-Qi Jia; Cha-Xiang Guan; Jia-Hao Tao; Yong Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-05-29       Impact factor: 7.310

Review 2.  The Role of Fibroblast Growth Factor 19 Subfamily in Different Populations Suffering From Osteoporosis.

Authors:  Xiawen Yu; Yue Xia; Jue Jia; Guoyue Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

Review 3.  FGF19 subfamily members: FGF19 and FGF21.

Authors:  Katarzyna Dolegowska; Malgorzata Marchelek-Mysliwiec; Monika Nowosiad-Magda; Michal Slawinski; Barbara Dolegowska
Journal:  J Physiol Biochem       Date:  2019-03-29       Impact factor: 4.158

4.  Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer.

Authors:  Yea Eun Kang; Jung Tae Kim; Mi Ae Lim; Chan Oh; Lihua Liu; Seung-Nam Jung; Ho-Ryun Won; Kyungmin Lee; Jae Won Chang; Hyon-Seung Yi; Hyun Jin Kim; Bon Jeong Ku; Minho Shong; Bon Seok Koo
Journal:  Cancers (Basel)       Date:  2019-08-12       Impact factor: 6.639

5.  Functional validity, role, and implications of heavy alcohol consumption genetic loci.

Authors:  Andrew Thompson; James Cook; Hélène Choquet; Eric Jorgenson; Jie Yin; Tarja Kinnunen; Jeff Barclay; Andrew P Morris; Munir Pirmohamed
Journal:  Sci Adv       Date:  2020-01-15       Impact factor: 14.136

6.  FGFR4 c.1162G > A (p.Gly388Arg) Polymorphism Analysis in Turkish Patients with Retinoblastoma.

Authors:  Demet Akdeniz Odemis; Seref Bugra Tuncer; Arash Adamnejad Ghafour; Khariga Jabbarli; Yasemin Gider; Betul Celik; Gozde Kuru Turkcan; Ozge Sukruoglu Erdogan; Seda Kilic Erciyas; Mukaddes Avsar; Rejin Kebudi; Sema Buyukkapu Bay; Samuray Tuncer; Hulya Yazici
Journal:  J Oncol       Date:  2020-12-30       Impact factor: 4.375

7.  Serum β-klotho is a potential biomarker in the prediction of clinical outcomes among patients with NSCLC.

Authors:  Juan Zhou; Suqin Ben; Tan Xu; Liqin Xu; Xin Yao
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

8.  Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis.

Authors:  Houwei Zhu; Yanqing Qu
Journal:  Oncol Lett       Date:  2019-12-17       Impact factor: 2.967

9.  Fibroblast growth factor receptor 4 as a prognostic indicator in triple-negative breast cancer.

Authors:  Wei Wei; Shiyu Cao; Jing Liu; Yuhang Wang; Quanfu Song; Leha A; Shanshan Sun; Xianyu Zhang; Xiaoshuan Liang; Yongdong Jiang
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

10.  Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.

Authors:  Masami Yamauchi; Atsushi Ono; Akira Ishikawa; Kenichiro Kodama; Shinsuke Uchikawa; Haruna Hatooka; Peiyi Zhang; Yuji Teraoka; Kei Morio; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Daiki Miki; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Clair Nelson Hayes; Masashi Fujita; Hidewaki Nakagawa; Wataru Yasui; Hiroshi Aikata; Kazuaki Chayama
Journal:  Clin Transl Gastroenterol       Date:  2020-05       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.